title: A double-blind comparative study of doxazosin and nitrendipine in patients with mild-to-moderate essential hypertension.
abstract: The antihypertensive efficacy and safety of doxazosin, a selective alpha 1-inhibitor, were compared with nitrendipine. Seventy-two hypertensive patients were entered into the 18-week, double-blind parallel group study, which involved three phases: a 4-week baseline period, a 10-week period in which patients received 1 to 8 mg of doxazosin or 10 and 20 mg of nitrendipine once daily, and a 4-week maintenance period. For all patients, the mean final daily doses were 2.5 mg for doxazosin and 13.9 mg for nitrendipine. In efficacy evaluable patients the percentages of therapy successes (standing diastolic blood pressure less than or equal to 90 mm Hg with greater than or equal to 5 mm Hg reduction or greater than or equal to 10 mm Hg decrease) were comparable for doxazosin (94%) and nitrendipine (91%), as was the proportion in whom blood pressure was "normalized" (standing diastolic blood pressure less than or equal to 90 mm Hg), 91% and 85, respectively. Blood pressures (diastolic and systolic in supine and standing positions) were significantly reduced (p less than 0.05) at all visits in both treatment groups. Ten patients (28%) in each treatment group experienced at least one adverse event. No clinically significant laboratory changes were apparent in either the doxazosin or nitrendipine groups, and no trends were observed with regard to organ systems or correlations with dose or duration of treatments. The investigators' global assessment of efficacy was rated excellent or good for all doxazosin-treated patients and excellent or good for 32 and fair for four in the nitrendipine group.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: W
authors.initials: W
authors.lastname: Nechwatal
authors.forename: J
authors.initials: J
authors.lastname: Berger
authors.forename: W
authors.initials: W
authors.lastname: Blumrich
authors.forename: H
authors.initials: H
authors.lastname: Bouzo
authors.forename: K
authors.initials: K
authors.lastname: Brandl
authors.forename: S
authors.initials: S
authors.lastname: Braun
authors.forename: A
authors.initials: A
authors.lastname: Laukaitis
authors.forename: G
authors.initials: G
authors.lastname: Müller
authors.forename: W
authors.initials: W
authors.lastname: Ryba
authors.forename: J
authors.initials: J
authors.lastname: Schreiegg
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003327:Coronary Disease / Q000517:prevention & control; D004311:Double-Blind Method; D017292:Doxazosin; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009568:Nitrendipine / Q000009:adverse effects / Q000627:therapeutic use*; D011224:Prazosin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D008055:Lipids; D009568:Nitrendipine; D017292:Doxazosin; D011224:Prazosin